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Abstract
Establishing robust links among gene expression, pathways and phenotypes is critical for understanding diseases and
developing treatments. In recent years there have been many efforts to develop the computational means to traverse
from genes to gene expression, model pathways and classify phenotypes. Numerous ontologies and other controlled
vocabularies have been developed, as well as computational methods to combine and mine these data sets and
establish connections. Here we discuss these efforts and identify areas of future work that could lead to a better
integration of genes, pathways and phenotypes to provide insights into the mechanisms under which gene
mutations affect expression and pathways and how these effects are manifested onto the phenotype.
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Introduction
A fundamental aspect of disease research involves the
understanding of biological processes that underpin
observed phenotypes. In order to achieve this level of
understanding, diseases need to be described as collec-
tions of measured phenotypes and these phenotypes need
to be analysed in relation to their genetic causes and
genomic effects and linked with information on molecu-
lar interactions. One consequence of these efforts could
be the ability to produce predictive models of phenotypes
from genomic profiles with the aim of describing diseases
more accurately. Such models will be helpful in under-
standing the genetic basis and molecular mechanisms
leading to complex or rare developmental diseases and the
process of ageing, as well as the characterisation and pro-
gression of cancer types. In particular, models built from
model organism datasets can be translated into insights
on humans in areas such as disease gene identification and
drug target testing.
Methods for assigning genotypes to phenotypes have
been developed and used intensively [1-3]. Thesemethods
include genome wide association studies (GWAS) that are
applied to identify causative genotypes for various con-
ditions and phenotypes. For example, a case-controlled
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genome wide association study identified five loci to be
associated with the susceptibility of osteoarthritis [4].
However, the identification of loci (and with that the geno-
type) still leaves a gap as to what molecular mechanisms
are at play to yield the observed phenotype. As a conse-
quence, GWAS studies are usually followed by functional
experiments, trying to unravel the biological mechanisms
that could influence the phenotype given the identified
genotype.
A functional follow-up experiment to fill the gap
between genotype and phenotype is the assessment of
expression levels of genes in the vicinity of the identified
GWAS loci in one or more tissues. In the study concern-
ing osteoarthritis [4], the authors investigated further the
gene expression and the protein expression of associated
genes using RT-PCR (genes) and immunohistochemical
staining. Through these functional studies, they identified
high levels of nucleostemin (encoded by the GNL3 gene)
in osteoarthitis patients.
A potential next step in connecting the identified geno-
type with the phenotype is to establish a link between the
expression of genes and the observed phenotypes, which
has been attempted by numerous studies [5-7]. A recent
example involves the characterisation of phenotypes in
yeast using high-throughput transcriptomic analyses [5].
Data classification methods have been used extensively
to characterise healthy or diseased tissue [6] from the
context of gene expression.
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In the examples of the GWAS and high-throughput gene
expression studies, although the genetic and genomic out-
comes of the disease can be associated with phenotypes,
the biological events leading to the phenotype at the sys-
tems level are not discovered. Signalling and metabolic
pathway analyses can inform on the specific mechanisms
of the genetic causes of the phenotypes. Recent work by
Harper et al. [8] presents a method for augmenting path-
way data with phenotypes from high-throughput genetic
screens in bacteria in order to discover causative genes.
To date, many databases (e.g. [9-11]) and ontologies (e.g.
[12-14]) have been developed to describe genes, path-
ways and phenotypes across different species (see Figure 1
and Additional file 1). However, the semantic integra-
tion of these resources needed to computationally anal-
yse the experimental set-up described above, is still at
its infancy. This hinders the development of generalised
data analysis methods that combine genes, gene expres-
sion, pathways and phenotypes. Here, we identified three
areas of research that need to be further developed in
order to facilitate computational prediction of the biolog-
ical mechanisms that link genotypes to phenotypes: (i)
the ontological characterisation of phenotypes, (ii) linking
gene expression and phenotypes and (iii) linking pathways
and phenotypes. We describe the current state-of-the-art
for each of the three areas in the following sections indi-
vidually and highlight potential future challenges where
identified.
Ontological characterisation of phenotypes
Due to the availability of phenotype data from several
model organisms (see Figure 1, e.g., phenotypes from
the International Mouse Phenotyping Consortium [15]),
options are not limited to human systems but may include
data from several different species. Furthermore, data
obtained through different experiments and stored in
different data resources can vary in the detail the infor-
mation is represented with [16]. As a consequence, three
major aspects of data integration need to be addressed:
(i) the integration across the different levels of complex-
ity within an organism, (ii) the integration across species,
and (iii) the frequencies of occurrences of phenotypes
(quantification). These three aspects are further illus-
trated in Figure 2. To facilitate data integration, numerous
Figure 1 Databases and ontologies for information on genes, pathways and phenotypes. The diagram shows the information flow from
genes to phenotypes via pathways. There are a large number of databases storing gene expression and other genomic data, with most of them
species specific that include links to a phenotype ontology term. In addition, there is a large number of phenotype ontologies that are not organism
specific, such as a mammalian phenotype ontology and the cellular phenotype ontology (CMPO). There exist a few databases providing genotype
to phenotype links, although most of this information is covered by species specific genomic databases. There are many small-scale species specific
or pathway-type specific databases and a few large general pathway databases (KEGG, Pathway Commons, REACTOME). Pathway ontologies exist
but are not widely used yet. Although in general there are good links among genes and pathways and genes and phenotypes, associations
between pathways and phenotypes are lacking.
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Figure 2 Three challenges when representing and comparing phenotypes. The diagram illustrates the three challenges that need to be
overcome in order to link gene expression and phenotypes using pathways: (A) the integration across the different levels of complexity within an
organism, (B) the integration across species, and (C) the frequencies of occurrences of phenotypes (quantification) – purple colour represents
individuals possessing phenotype of interest (examples in parentheses taken from Angelman syndrome in OrphaNet).
ontologies have been developed that define the meaning
of biological concepts, such as the Gene Ontology (GO)
[13].
Integration across different levels of organismal
complexity
Phenotypes span different levels of complexity and range
from a molecular level to the entire organism, such as
the cellular level, the tissue level or the organ level (see
Figure 2(A)) [17]. Existing biomedical ontologies cover
several levels of complexity, e.g., ontologies that repre-
sent gene function (GO) as well as tissue information
(e.g. BRaunschweig ENzyme DAtabase (BRENDA) tissue
ontology (BTO) [14]) or organism level (e.g. the Mam-
malian Phenotype Ontology (MP) [12] or the Human
Phenotype Ontology (HPO) [18]). In order to facilitate
reasoning over the different levels of complexity needed
to describe an individual with ontologies, the ontolo-
gies have to be aligned and mapped to one another.
While mapping efforts are ongoing to align ontolo-
gies across species covering the same level of com-
plexity, e.g., the alignment of anatomy as provided by
UBERON [19], the seamless integration of ontologies
across the different levels of complexity is still ongoing
work.
Integration across species
In order to computationally compare phenotypes across
different species, the existing phenotype data needs to
be semantically annotated in a way that would facilitate
the comparison. Traditionally, model organisms as well
as human data were semantically represented using pre-
composed phenotype ontologies. In a pre-composed phe-
notype ontology such as MP or HPO, one concept cor-
responds to one phenotype and can directly be used
for annotation. However, a comparison is only possible
as long as the same pre-composed ontology is used for
annotation.
To overcome this limitation of pre-composed pheno-
type ontologies, post-composed phenotype representa-
tions have been suggested. One approach that is broadly
used, for example to post-compose MP and HPO and
represent zebrafish mutants in the Zebrafish Model
Organism database [20], is the description of phenotypes
using Entity-Quality (EQ) statements. Entity-Quality (EQ)
statements enable the composition of phenotypes using
species-independent ontologies [21], e.g. GO (for the rep-
resentation of processes) or UBERON (a cross-species
anatomy ontology). While some of the statements have
been generated and verified automatically [22], manual
verification is still needed to ensure the correct repre-
sentation. How species can be compared based on pre-
and post-composed phenotype annotations is illustrated
in Figure 2(B).
The applicability of the generated EQ statements is
demonstrated by their usage in a variety of projects,
which e.g., predict the involvement of genes in diseases
and pathological processes [2,3] and gene function [23].
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Despite the successful applications of pre- and post-
composed phenotype annotations, the harmonised appli-
cation of phenotypes in conjunction with gene, expression
and pathway data is still very limited.
Frequencies of occurring phenotypes
The quantification of phenotype data is beginning to
become available: databases such as OrphaNet [24]
describe disease phenotypes with additional quantifiers,
e.g., the phenotype dwarfism (OrphaNet clinical sign
id: 53350) is very frequent in patients with a 12q14
micro deletion syndrome (OrphaNet disorder id: 12544)
or the phenotype strabismus (OrphaNet clinical sign id:
5870) is occurring occasionally in patients with Angel-
man syndrome (OrphaNet disorder id: 90). OrphaNet
assigns phenotype annotations and frequency informa-
tion represented with an OrphaNet-specific vocabulary
(see Figure 2(C)).
A similar strategy has been applied to annotate human
genetic disorders described in the Online Mendelian
Inheritance inMan (OMIM) database [9]. Each disorder is
described using concepts of the HPO and, optionally, fre-
quency information can be added to each of the assigned
phenotype annotation [25]. Despite great efforts, fre-
quency information is not available for all the annotations
assigned and only available via the download file.
While clinical databases already work on the inclu-
sion of quantified phenotype data, model organism
databases lag behind by not providing this information.
Thus, quantified phenotype information cannot yet be
used for cross-species data analysis and computational
modelling.
Linking gene expression to phenotypes
The ease of obtaining whole genome expression datasets
has enabled more thorough classification of phenotypes
associated with the expression of sets of genes [6]. A large
number of studies attempt to identify groups of genes
whose expression is responsible for a particular pheno-
type, such as disease or tissue morphology [26]. More
complex experimental designs attempt to associate the
phenotype with dynamic or systems views of gene expres-
sion [27]. The techniques used to link the phenotype
to causative patterns of gene expression largely depend
on the experimental design and the technology used to
profile gene expression.
Gene expression signatures
In order to characterise a phenotype in terms of gene
expression, most studies attempt to identify the minimum
number of genes whose expression patterns determine the
phenotype in question. This group of genes is referred to
as a “gene signature” in the literature and once defined and
validated has important practical applications to disease
diagnosis and prognosis, as well as the discovery of new
therapies. In cancer genomics, for example, classifications
of tumour types from high-throughput gene expression
and/or copy number profiles have helped unravel the
complexity of different cancer types and have led to a bet-
ter understanding of cancer progression and the identifi-
cation of new diagnostic biomarkers. For example, Marisa
et al. [6] produced a transcriptome-based classification of
566 colon cancer samples to discover six different molec-
ular subtypes of the disease, that associated with distinct
clinicopathological characteristics and corresponded to
different relapse times. Aravinthan et al. [28] defined a
signature of 40 genes that appear upregulated in hepato-
cyte senescence as opposed to controls and then validated
this by finding enrichment of these genes in public data
sets representing liver conditions such as steatohepatitis,
alcohol-related hepatitis and HCV-related cirrhosis [28].
Given enough data sets, existing data mining methods
can assign patterns of gene expression to the phenotypes
under study. Although the linkage of gene expression sig-
natures to phenotype associations is an important step
in determining the causal link between genotypes and
phenotypes, it is still difficult to establish the underly-
ing biological mechanism from gene expression data sets
alone.
Complex experimental designs
More complex experimental designs are used in order to
refine the mechanisms under which gene expression can
lead to a certain phenotype. Here, the experimental design
attempts to address issues such as the influence of envi-
ronmental factors, time and interplay between tissues. An
individual study example comes from the work by Äijö
et al. [27] where statistical modelling based on Gaussian
processes is used to analyse the differentiation of human
Th17 cells. The authors expose CD4+ T cells to two dif-
ferent types of ligands and record the gene expression
using RNA-seq over five different time-points. The anal-
ysis can describe the dynamics and provide insight into
the kinetics of gene expression that lead to the different
outcomes of T cell activation depending on the ligands
used.
Tissue-specific and temporal based gene expression
with matching phenotype measurements could be identi-
fied by appropriate experimental controls. However, these
are often absent or impractical to implement in large-
scale phenotyping assays or in cases ofmeta-analyses from
already available data sets [7]. Generally, formore complex
experimental designs to be more case-specific, custom-
made computational solutions are usually required in
order to analyse the gene expression data according to
the different variables. Efforts are being made to gener-
alise these tools and resources so that analysis of complex
designs can be made easier. Examples include software
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for the analysis of time-series data sets. The DyNB tools
suite in [27] and NextmaSigPro [29] are examples of
software tools that enable analysis of time-series data
sets.
Efforts have also been made to tackle the complexities
of tissue specific gene expression in whole organism gene
expression data sets by developing resources such as tis-
sue specific gene expression atlases [30-32]. These data
sets can be used as benchmarks to explore experiments
on whole organisms. Small organisms such as Drosophila
Melanogaster are difficult to dissect on a large scale and
sometimes tissue specific expression must be inferred
from whole body profiles, rather than directly measured.
Innocenti et al. [33] extracted tissue specific genes from
whole fly gene expression by use of FlyAtlas [30,34]. FlyAt-
las is a database that holds information on genes expressed
in 25 adult fly tissues originally obtained by tissue specific
microarray profiling in wild type flies.
Gene expression analyses are very useful in identify-
ing groups of genes that could characterise a pheno-
type. Although they do not provide much detail on the
specific mechanisms under which the original stress or
mutation leads to the observed phenotype, they can be
used as a starting point for subsequent analyses that
can narrow down candidate pathways and processes and
generate hypotheses for more detailed experiments that
can eventually shed light on the exact causes of the
phenotype.
Linking pathways to phenotypes
Deriving the underlying mechanism of the phenotype,
given the initial mutations and/or resulting gene expres-
sion, involves the integration of knowledge on pro-
tein interactions and pathways [35]. There are different
types of pathway analyses frequently used depending
on the nature of the pathways: protein-protein inter-
actions; gene-regulatory pathways; quantitative reaction
modelling that includesmetabolic, pharmacokinetic mod-
elling. Methods for analysing these types of pathways have
been previously reviewed in [35,36]. Linking these types
of analyses with gene expression depends on whether
there are already candidate pathways of interest and what
is their degree of annotation. It also depends on the
hypotheses of the studies investigated and whether they
involve a small and specific pathway where knowledge of
quantitative reactions matter and are available or whether
they involve a large integrational study where broadness
of pathway connections are important, usually at a cost of
using detailed quantitative information on the kinetics of
the interactions involved.
Pathwaymodels
Data for quantitative pathway analyses usually come from
direct protein level measurements, therefore enabling the
use of computational simulations for the formulation of
predictive hypotheses that can subsequently be tested
experimentally. Such approaches have the potential to
produce predictive mathematical models describing the
underlying mechanisms at high-levels of detail [37].
Panetta et al. [38] study the variations of methotrexate
accumulation in cells of acute lymphoblastic leukemia
patients using pharmacokinetic and pharmacodynamic
models. By employing these methods they characterise
how perturbations in the folate pathway, target of
methotrexate, vary across the tumour subtypes (pheno-
types) and how they relate to genetic variation and gene
expression.
Quantitative pathway modelling methods are not easy
to implement on a large scale and are mostly useful
when there is already substantial knowledge of the bio-
logical process involved. In cases where the underlying
biological process is unknown or poorly defined, high-
throughput protein interaction data or high-level pathway
information from pathway databases can help disentan-
gle the mechanisms that are responsible for or induced
by the observed gene expression. Boolean logic and other
logic-based approaches, such as [39,40], have been used
successfully for qualitative pathway analyses, to gener-
ate hypotheses that link gene expression, pathways and
phenotypes.
Knowledge integration
Pathway databases such as REACTOME [10] or KEGG
[41] contain a wide range of developmental, signalling,
metabolic, as well as disease pathways. These are well-
linked to other resources, such as Ensembl [11] and
Uniprot [42], for better integration with gene and protein
information. Currently they support pathway enrichment
analyses for a set of interesting genes or proteins and
provide tools for visualising the pathways in the context
of these interesting molecules. In addition, REACTOME
provides ontological links between pathways, therefore
allowing the exploration of interactions and relationships
across different pathways. Often these pathway resources
do not contain exactly the same pathways and in order
to enable more comprehensive analyses, their data sets
need to be merged. Resources such as BioSystems [43]
attempt to collect and disseminate all available pathways
from the available databases. However, due to lack of a
widely used controlled vocabulary describing the avail-
able pathways, such attempts fail to fully semantically
integrate data from different pathway databases. There
has been significant progress in developing ontologies
and standard formats for descriptions of pathway compo-
nents and reactions (SBO, SBML, [44]). However, these
have mainly been focused on describing the mathematical
interactions within pathways in order to enable simula-
tions. Therefore, they have not been widely adopted by
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all pathway databases in order to enable more effective
integration.
Further work also needs to focus on linking the differ-
ent levels of information, protein levels, gene expression
andmetabolic and signalling pathways into computational
models that can handle qualitative and quantitative path-
way parameters. Integrating different kinds of data sets
from different species to solve a single, common biologi-
cal process is an invaluable step in pathway analyses, but
remains a difficult task. Advances in text-mining meth-
ods, as well as more accurate orthologous relationships
between the genes of different species will help overcome
these problems.
A major remaining problem in the linkage of genes and
their expression signatures to pathways to phenotypes is
the limited knowledge of the mapping between pathways
and phenotypes. This is a difficult task mainly due to the
lack of appropriate data sets that would enable the infer-
ence of such connections on the large scale. However,
high-throughput phenotyping projects such as the Inter-
national Mouse Phenotyping Consortium [15] have the
potential to provide sufficient data sets for the inference
of such links.
Finally, recent efforts on multi-scale models of organs
attempt to bridge the gap between molecular pathways
and physiology through projects such as the Virtual Phys-
iological Human [45] and the Virtual Liver, a collaborative
effort to produce a physiological model of the liver that
interacts with pathways and other molecular component
in order to support simulations and the understanding of
the liver function in health and disease [46]. Such efforts
are still in their initial steps but have the potential to facil-
itate a better understanding of the relationship between
genes and phenotypes.
Conclusions
High-resolution gene expression data sets are provid-
ing more insight into the functional consequences of the
genotype as well as clues into the mechanisms that might
control the phenotype. At the same time, research utilising
pathway analysis and data integration has been increas-
ingly important in explaining the biological mechanisms
under which genotypes (and gene expression) influence
phenotypes. Some form of pathway analysis is routinely
part of gene expression studies. However, this is hindered
by the lack of detailed pathway maps and quantitative
information on the reactions. From the perspective of
phenotype characterisation, the development of different
types of ontologies and links between them is increas-
ingly improving the integration of gene, tissue, anatomical
and disease data sets within and between species. These
improvements are creating the basis for more detailed
associations between genes, pathways and phenotypes in
the future.
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